While many medical centers around the world depend on external labs to genetically engineer patient T-cells, a process that can take up to a few months and hinder the therapy’s effectiveness, Sheba completes the entire treatment process in less than two weeks thanks to its specialized in-house laboratory. However, not all patients respond to the […]

As part of the REACT 2023 regional conference, which took place on Monday, March 20th, Sheba’s premier physicians showcased the latest in oncologic care, focusing on pediatrics, marking a significant breakthrough for Israeli-Palestinian medical cooperation. A leader in clinical care, research, and innovation, Sheba is committed to not only offering world-class care to all patients, […]

CAR T-cell therapy is a revolutionary blood cancer treatment that helps the body combat tumors using its own T-cells. The therapy involves collecting the patient’s blood, separating T-cells, and genetically engineering them to produce chimeric antigen receptors (CARs). These allow the T-cells to recognize tumor cells, targeting and destroying them. After their alteration, T-cells are […]

A decade of innovation behind us, and another in front: Sheba celebrates its medical breakthroughs

The International Society for the Study of Pleura and Peritoneum designated Sheba’s Surgical Oncology department as an International PIPAC Teaching Center

Acute myeloid leukemia (AML) is one of the most serious, complex cancers. Infection with the novel coronavirus can be deadly for AML patients.